Vast Life Sciences Inc

Vast Life Sciences Inc, operating under the name Pragma Bio, leverages an AI-enabled, biology-first approach to discover novel small molecules that target the gut-immune axis, addressing significant challenges in current drug discovery methods. By utilizing phenotypic screens and mining clinically-relevant biosynthetic gene clusters, they aim to uncover new pathways and reduce clinical trial failure rates associated with traditional target-first approaches.

With their innovative platform, PIKASO, Pragma Bio combines bioinformatics, synthetic biology, and pharmacology to create a seamless end-to-end discovery pipeline for transforming gut-derived small molecules into effective new medicines. Their unique capabilities in mining naturally evolved molecules position them as leaders in the biopharma sector, driving the development of transformative therapeutics.

Generated from the website